PVLA Stock Summary and Trading Ideas (Palvella Therapeutics | NASDAQ:PVLA)

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Palvella Therapeutics trades on the NASDAQ stock market under the symbol PVLA.

As of June 8, 2026, PVLA stock price declined to $105.25 with 365,157 million shares trading.

PVLA has a beta of 1.18, meaning it tends to be more sensitive to market movements. PVLA has a correlation of 0.04 to the broad based SPY ETF.

PVLA has a market cap of $1.51 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that PVLA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

PVLA has outperformed the market in the last year with a return of +348.1%, while the SPY ETF gained +25.9%. However, in the most recent history, PVLA shares have underperformed the stock market with its stock returning -22.0% in the last 3 month period and -7.7% for the last 2 week period, while SPY has returned +8.8% and -0.9%, respectively.

PVLA support price is $103.95 and resistance is $113.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PVLA shares will trade within this expected range on the day.